Literature DB >> 25840648

The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum.

Robert L Rosenfield1.   

Abstract

BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common cause of chronic hyperandrogenic anovulation. Two-thirds of PCOS patients have functionally typical PCOS, with typical functional ovarian hyperandrogenism manifest as 17-hydroxyprogesterone hyper-responsiveness to gonadotropin stimulation. Most, but not all, of the remainder have atypical functional ovarian hyperandrogenism. Many asymptomatic volunteers with polycystic ovary morphology (PCOM) have similar abnormalities.
OBJECTIVE: The objective of this paper is to review the relationship of biochemical ovarian function to the clinical spectrum observed in PCOS and in normal volunteers with PCOM.
FINDINGS: Adolescents and adults with PCOS are similar clinically and biochemically. Ninety-five percent of functionally typical PCOS have classic PCOS, ie, hyperandrogenic anovulation with PCOM. In addition to having more severe hyperandrogenism and a greater prevalence of PCOM than other PCOS, they have a significantly greater prevalence of glucose intolerance although insulin resistance is similarly reduced. Half of normal-variant PCOM have PCOS-related steroidogenic dysfunction, which suggests a PCOS carrier state.
CONCLUSIONS: There is a spectrum of ovarian androgenic dysfunction that ranges from subclinical hyperandrogenemia in some normal-variant PCOM to severe ovarian hyperandrogenism in most classic PCOS. A minority of mild PCOS cases do not fall on this spectrum of ovarian androgenic dysfunction, but rather seem to have obesity as the basis of their hyperandrogenism, or, less often, isolated adrenal androgenic dysfunction. Half of normal-variant PCOM also do not fall on the PCOS spectrum, and some of these seem to have excessive folliculogenesis as a variant that may confer mild prolongation of the reproductive lifespan. Improved understanding of PCOM in young women is needed.
Copyright © 2015 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glucose intolerance; Insulin resistance; Obesity; Polycystic ovary; Polycystic ovary syndrome

Mesh:

Substances:

Year:  2014        PMID: 25840648      PMCID: PMC4387116          DOI: 10.1016/j.jpag.2014.07.016

Source DB:  PubMed          Journal:  J Pediatr Adolesc Gynecol        ISSN: 1083-3188            Impact factor:   1.814


  70 in total

Review 1.  The diagnosis of polycystic ovary syndrome in adolescents.

Authors:  Enrico Carmina; Sharon E Oberfield; Rogerio A Lobo
Journal:  Am J Obstet Gynecol       Date:  2010-05-01       Impact factor: 8.661

Review 2.  Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity.

Authors:  Robert L Rosenfield; Brian Bordini
Journal:  Brain Res       Date:  2010-09-25       Impact factor: 3.252

3.  Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries.

Authors:  D Dewailly; H Gronier; E Poncelet; G Robin; M Leroy; P Pigny; A Duhamel; S Catteau-Jonard
Journal:  Hum Reprod       Date:  2011-09-16       Impact factor: 6.918

4.  Polycystic ovarian morphology in postmenarchal adolescents.

Authors:  Ethel Codner; Claudio Villarroel; Francisca C Eyzaguirre; Patricia López; Paulina M Merino; Francisco Pérez-Bravo; Germán Iñiguez; Fernando Cassorla
Journal:  Fertil Steril       Date:  2010-07-21       Impact factor: 7.329

5.  Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test.

Authors:  Robert L Rosenfield; Monica Mortensen; Kristen Wroblewski; Elizabeth Littlejohn; David A Ehrmann
Journal:  Hum Reprod       Date:  2011-09-09       Impact factor: 6.918

6.  Oligoovulatory and anovulatory cycles in women with polycystic ovary syndrome (PCOS): what's the difference?

Authors:  Janneke A Burgers; Sharon Lie Fong; Yvonne V Louwers; Olivier Valkenburg; Frank H de Jong; Bart C J M Fauser; Joop S E Laven
Journal:  J Clin Endocrinol Metab       Date:  2010-09-15       Impact factor: 5.958

7.  Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes.

Authors:  Ettore Guastella; Rosa Alba Longo; Enrico Carmina
Journal:  Fertil Steril       Date:  2010-03-19       Impact factor: 7.329

8.  Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone.

Authors:  C Villarroel; P M Merino; P López; F C Eyzaguirre; A Van Velzen; G Iñiguez; E Codner
Journal:  Hum Reprod       Date:  2011-07-21       Impact factor: 6.918

9.  The polycystic ovary post-rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance.

Authors:  Erica B Johnstone; Mitchell P Rosen; Rebecca Neril; Deborah Trevithick; Barbara Sternfeld; Rosemary Murphy; Carolyne Addauan-Andersen; Daniel McConnell; Renee Reijo Pera; Marcelle I Cedars
Journal:  J Clin Endocrinol Metab       Date:  2010-08-18       Impact factor: 5.958

10.  Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis.

Authors:  M Hickey; D A Doherty; H Atkinson; D M Sloboda; S Franks; R J Norman; R Hart
Journal:  Hum Reprod       Date:  2011-04-08       Impact factor: 6.918

View more
  12 in total

Review 1.  Magnetic resonance imaging of acquired disorders of the pediatric female pelvis other than neoplasm.

Authors:  Mougnyan Cox; Sharon W Gould; Daniel J Podberesky; Monica Epelman
Journal:  Pediatr Radiol       Date:  2016-05-26

2.  AMH is Higher Across the Menstrual Cycle in Early Postmenarchal Girls than in Ovulatory Women.

Authors:  Madison T Ortega; Lauren Carlson; John A McGrath; Tairmae Kangarloo; Judith Mary Adams; Patrick M Sluss; Geralyn Lambert-Messerlian; Natalie D Shaw
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

Review 3.  New perspectives on the definition and management of polycystic ovary syndrome.

Authors:  R Pasquali; A Gambineri
Journal:  J Endocrinol Invest       Date:  2018-01-23       Impact factor: 4.256

Review 4.  [Cutaneous manifestations of metabolic syndrome].

Authors:  G Holzer; B Straßegger; B Volc-Platzer
Journal:  Hautarzt       Date:  2016-12       Impact factor: 0.751

5.  The Effect of the Testis on the Ovary: Structure-Function Relationships in a Neonate with a Unilateral Ovotestis (Ovotesticular Disorder of Sex Development)
.

Authors:  Siri Atma W Greeley; Elizabeth Littlejohn; Aliya N Husain; Darrel Waggoner; Mohan Gundeti; Robert L Rosenfield
Journal:  Horm Res Paediatr       Date:  2017-03-02       Impact factor: 2.852

6.  Adolescent polycystic ovary syndrome due to functional ovarian hyperandrogenism persists into adulthood.

Authors:  Robert L Rosenfield; David A Ehrmann; Elizabeth E Littlejohn
Journal:  J Clin Endocrinol Metab       Date:  2015-02-12       Impact factor: 5.958

7.  Correlation of Clinical, Hormonal, Biochemical and Ultrasound Parameters Between Adult and Adolescent Polycystic Ovarian Syndrome: Adult and Adolescent PCOS.

Authors:  Shivi Jain; Madhu Jain; R C Shukla
Journal:  J Obstet Gynaecol India       Date:  2021-10-09

Review 8.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

9.  Polycystic ovarian morphology is associated with primary dysmenorrhea in young Korean women.

Authors:  Jee Young Jeong; Min Kyoung Kim; Inha Lee; Jisun Yun; Young Bin Won; Bo Hyon Yun; Seok Kyo Seo; SiHyun Cho; Young Sik Choi; Byung Seok Lee
Journal:  Obstet Gynecol Sci       Date:  2019-07-22

10.  Reporting quality of polycystic ovary syndrome practice guidelines based on the RIGHT checklist.

Authors:  Hongzhu Li; Yu Zhang; Liming Lu; Wei Yi
Journal:  Medicine (Baltimore)       Date:  2020-10-16       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.